There was no evidence of a difference in the risk for kidney failure associated with Lp(a) across subgroups defined by age, sex, race/ethnicity, diabetes, systolic blood pressure, history of CHD, stroke, or PAD, eGFR, albumin-creatinine ratio, high-sensitivity C-reactive protein, aspirin use, or statin use. This evidence concerns the gene LPA and coronary artery disorder.